Optima Health Exceeds FY26 EBITDA Expectations by 10% Following PAM Acquisition

Optima Health’s FY26 trading update: EBITDA c.10% ahead of expectations

Optima Health has delivered a tidy beat. In today’s unaudited trading update for the year to 31 March 2026, the AIM-listed occupational health specialist said adjusted EBITDA is expected to come in about 10% ahead of market expectations. With consensus at £18.1 million, that implies something in the region of £19.9 million on a simple read-across, though the company has not given a precise figure.

The update also confirms two other notable developments: completion of the PAM acquisition on 26 March 2026 and the settlement of a previously disclosed procurement matter, which delivered £4.7 million of other operating income across H1 and H2. Management says performance in H2 was strong and ahead of expectations, with momentum underpinned by progress against medium-term targets and the step-change from PAM.

What Optima actually said – and why it matters

Optima expects FY26 adjusted EBITDA to be about 10% above consensus. That’s a clean positive surprise, particularly given it follows stronger trading commentary on 31 March. In plain English: the business made more profit at the operating level (before interest, tax, depreciation and amortisation, and adjusted for certain items) than the market had pencilled in.

There’s also a clear nod to scale and ambition. The company reiterated its medium-term targets of £200 million revenue and £40 million adjusted EBITDA. The newly enlarged group – thanks to PAM – is expected to benefit from “significant operational and cost synergies” that should help bridge the gap to those targets.

PAM acquisition: scale, synergies, and sector positioning

PAM completed on 26 March 2026, just before the year-end. While we do not have deal metrics in this RNS, the company calls it “transformational” and directly links it to greater presence in what it describes as an attractive and growing occupational health market. The strategic logic is straightforward: bigger footprint, more clinicians, and a larger client base create operating leverage and cost efficiencies.

Synergies – savings that come from combining operations – are called out as “significant” on both operational and cost fronts. Quantification is not disclosed, but investors should expect integration updates in the next detailed trading statement later in Q2 2026.

Procurement matter settled: £4.7 million recognised as other income

The previously disclosed procurement issue has been resolved. Optima recognised £2.3 million of other operating income in H1 FY26 and a further £2.4 million in H2 FY26. That is £4.7 million for the year.

Important nuance: this is disclosed as “other operating income”. Whether any of this features in adjusted EBITDA depends on the company’s exact definition, which is not set out here. Either way, it supports FY26 reported profit and cash generation optics, but investors should treat it as one-off in nature rather than recurring trading profit.

Key figures and milestones at a glance

FY26 adjusted EBITDA consensus	£18.1 million
Company guidance vs consensus	c.10% ahead
Indicative implied EBITDA (my calc)	c.£19.9 million
Other operating income recognised H1 FY26	£2.3 million
Other operating income recognised H2 FY26	£2.4 million
Total other operating income in FY26	£4.7 million
Medium-term revenue target	£200 million
Medium-term adjusted EBITDA target	£40 million
PAM acquisition completion	26 March 2026
Team and clinical footprint	More than 2,000 staff including 1,250 clinicians, 50+ clinics
Operations	UK and Ireland

Why this looks positive for shareholders

Beating expectations matters. Markets price shares based on forecasts, so any credible beat tends to nudge sentiment the right way. The company is also leaning into growth with PAM, which should enlarge its share of a market it calls attractive and growing.

The near-term setup is helpful: strong H2 trading, a recently settled procurement matter, and a larger platform that can absorb overheads more efficiently. If management can execute on the promised synergies and keep organic momentum going, those medium-term targets start to look more tangible.

But keep the caveats in mind

• Unaudited and high level: No FY26 revenue or cash detail here. We will need the Q2 trading update for the full picture.
• One-offs vs underlying: £4.7 million of other operating income supported FY26. It is not disclosed whether this is included in adjusted EBITDA, so treat it carefully when judging underlying run-rate.
• Integration risk: PAM closed late in the year. Synergy delivery is promised but unquantified. Timelines, costs to integrate, and client retention will matter.
• Targets vs trajectory: £200 million revenue and £40 million adjusted EBITDA are ambitious. Investors should look for stepping stones – quarterly momentum, margin progression, and evidence of synergy capture.

What to watch in the next update

• Clear FY26 numbers: revenue, adjusted EBITDA, cash flow, and any split between organic performance and one-offs.
• Synergy roadmap: scope, quantum, timing, and one-off integration costs tied to PAM.
• Growth commentary: pipeline and retention in core public and private sector customers in the UK and Ireland.
• Definition detail: explicit reconciliation of adjusted EBITDA and treatment of other operating income.

My take

This is a tidy, confidence-building update from Optima Health (AIM: OPT). Beating EBITDA expectations by about 10% is a meaningful signal, and the PAM deal adds heft in a market where scale matters. The settlement-driven other income is helpful this year but should be treated as non-recurring when assessing the underlying engine.

From here, it is all about execution. If management can quantify and deliver the “significant” synergies, protect service quality across 50+ clinics and 1,250 clinicians, and keep organic demand ticking up, the medium-term £40 million EBITDA target does not look far-fetched. I will be watching the Q2 trading update closely for the detail behind today’s upbeat headlines.